

Acute consumption of flavan-3-ol-enriched dark chocolate affects human endogenous metabolism

Luisa Martha Ostertag, Mark Philo, Ian J Colquhoun, Henri S Tapp, Shikha Saha, Garry G. Duthie, E. Kate Kemsley, Baukje de Roos, Paul A. Kroon, and Gwénaëlle Le Gall

J. Proteome Res., **Just Accepted Manuscript** • DOI: 10.1021/acs.jproteome.7b00089 • Publication Date (Web): 06 Jun 2017

Downloaded from <http://pubs.acs.org> on June 15, 2017

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.



1
2
3 **Acute consumption of flavan-3-ol-enriched dark chocolate affects human**
4 **endogenous metabolism**
5
6

7
8 Luisa M. Ostertag^{1,2}, Mark Philo¹, Ian J. Colquhoun¹, Henri S. Tapp¹, Shikha Saha¹,
9
10 Garry G. Duthie², E. Kate Kemsley¹, Baukje de Roos², Paul A. Kroon¹, Gwénaëlle Le
11
12 Gall^{1*}
13

14
15
16 ¹Quadram Institute Bioscience, Norwich Research Park, Norwich NR4 7UA, UK
17

18
19 ²Rowett Institute of Nutrition and Health, University of Aberdeen, Aberdeen AB24 3FX, UK
20

21
22 * gwenaelle.legall@quadram.ac.uk
23

24
25 Tel: +44(0)1603 255280
26

27 Fax: +44(0)1603 507723
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Flavan-3-ols and methylxanthines have potential beneficial effects on human health including reducing cardiovascular risk. We performed a randomized controlled cross-over intervention trial to assess the acute effects of consumption of flavan-3-ol-enriched dark chocolate, compared with standard dark chocolate and white chocolate, on the human metabolome. We assessed the metabolome in urine and blood plasma samples collected before and at 2 h and 6 h after consumption of chocolates in 42 healthy volunteers using a non-targeted metabolomics approach. Plasma samples were assessed and showed differentiation between time points with no further separation among the three chocolate treatments. Multivariate statistics applied to urine samples could readily separate the postprandial time points and distinguish between the treatments. Most of the markers responsible for the multivariate discrimination between the chocolates were of dietary origin. Interestingly, small but significant level changes were also observed for a subset of endogenous metabolites. ¹H NMR revealed that flavan-3-ol-enriched dark chocolate and standard dark chocolate reduced urinary levels of creatinine, lactate, some amino acids and related degradation products and increased the levels of pyruvate and 4-hydroxyphenylacetate, a phenolic compound of bacterial origin. This study demonstrates that an acute chocolate intervention can significantly affect human metabolism.

Keywords: NMR, MS, metabolomics, chocolate, metabolism, health, flavonoids, methylxanthines

INTRODUCTION

Dark chocolate contains at least two groups of bioactive substances, flavan-3-ols and methylxanthines. Well known flavan-3-ols include catechin, epicatechin gallate, epigallocatechin, epigallocatechin gallate, proanthocyanidins, theaflavins, thearubigins and they are regarded as functional food ingredients¹. The most well-known methylxanthines are theobromine, caffeine and theophylline. Dark chocolate is enriched in theobromine, with lesser amounts of caffeine and practically no theophylline².

1
2
3 Flavan-3-ols have various organoleptic properties such as astringency, bitterness, sourness,
4 and sweetness. They also have several beneficial health effects by acting as antioxidant,
5 anticarcinogen, antimicrobial, anti-viral, and neuro-protective agents. They are also known to
6 affect several measures of cardiovascular health, including blood pressure, vascular
7 function³, platelet function^{4,5}, plasma lipids and lipid peroxidation in humans.
8
9

10
11
12
13
14 The bioactive effects of methylxanthines are mainly mediated by the so-called adenosine
15 receptor blockers⁶. They may improve lung function². Methylxanthines increase the
16 thermogenic capacity of adipose tissue⁷. There is also a synergistic interaction between
17 caffeine and catechins in increasing thermogenesis on brown adipose tissue⁸.
18
19

20
21
22
23 Very few studies have identified the fate of cocoa components in humans or rodents^{9,10} and
24 such information may help to identify the bioactive compounds. Recently non-targeted
25 approaches in plasma and urine were employed to assess the changes in the host and
26 microbial metabolome after cocoa consumption in human subjects^{11,12}. Martin *et al.*¹² used
27 Nuclear Magnetic Resonance (NMR) and Mass Spectrometry (MS) approaches to examine
28 human fasted plasma and urine samples to assess the chronic effects of regular
29 consumption of dark chocolate. This study focused on endogenous metabolites involved in
30 energy homeostasis and stress responses but lacked a control group. Llorach *et al.*¹¹ on the
31 other hand, used a non-targeted Liquid Chromatography (LC)/MS method to identify
32 metabolites up to 24 h after ingestion of a cocoa drink in 10 subjects but the focus was on
33 the metabolites found in the cocoa product, the excretion of the polyphenols ingested and
34 their products.
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 Previously, we performed a randomized controlled human trial (clinicaltrials.gov;
50 NCT01099150) to evaluate the effect of flavan-3-ol-enriched dark chocolate, standard dark
51 chocolate and white chocolate on platelet function in healthy subjects¹³. Both flavan-3-ol-
52 enriched dark chocolate and white chocolate, improved several measures of postprandial
53
54
55
56
57
58
59
60

1
2
3 platelet function in a gender-specific way although the specific bioactive compounds could
4
5 not be determined.
6
7

8 In the current analysis, we employed samples from the same study to assess the effects of
9
10 acute consumption of flavan-3-ol-enriched dark chocolate, in comparison with standard dark
11
12 chocolate and white chocolate, on both plasma and urinary proton NMR (^1H NMR) profiles
13
14 and urinary MS profiles in 42 healthy humans having fasted ≥ 10 h overnight. Postprandial
15
16 assessment of the human metabolome by such complementary techniques provides further
17
18 insights into both the metabolism of flavan-3-ols and methylxanthines in the human body and
19
20 the effects these plant bioactives have on endogenous metabolism.
21
22
23
24
25

26 **MATERIAL AND METHODS**

27 *Subjects and study design*

28
29
30
31
32 Recruitment of subjects ($n = 42$) and details of the crossover study design were reported
33
34 previously¹³. The study was carried out in accordance with the ethical principles of the
35
36 Declaration of Helsinki and Good Clinical Practice. The study was approved by the Ethics
37
38 Committee of the Rowett Institute of Nutrition and Health, University of Aberdeen (reference
39
40 number 09-002) following review by the North of Scotland Research Ethics Committee. This
41
42 trial was registered at clinicaltrials.gov as NCT01099150. Volunteers were informed about
43
44 the purpose and the risks of the study, and written informed consent was obtained from all
45
46 subjects before participation.
47

48
49 The details are summarised in the Supporting Information Material and Methods, Figure S1
50
51 and Tables S1 and 2.
52

53 *Urine and blood sampling and creatinine assay*

1
2
3 Sampling and storage of biofluid samples was previously described¹³, as was measurement
4 of creatinine in urine. Relevant details are supplied in the Supporting Information.
5
6

7
8 *Extraction and analysis of flavonoid content of the chocolate bars*
9

10
11 First, lipids were removed from chocolate samples as described by Cooper *et al.*¹⁴. This
12 included the extraction of defatted and dried chocolate powder using 70% aqueous
13 methanol containing 0.1 mg/mL galangin (282200, Sigma-Aldrich) as internal standard.
14
15 Samples were heated to 70 °C for 20 min. Supernatants were filtered and filtrates from each
16
17 sample were analyzed by normal-phase HPLC as described previously. Samples were
18
19 analyzed in duplicate and the resulting flavonoid contents of the chocolate bars are shown in
20
21 (Table S3).
22
23
24

25
26 *NMR procedure*
27

28
29
30 Urine samples were thawed at room temperature and prepared for ¹H NMR spectroscopy by
31
32 mixing 500 μL urine with 50 μL phosphate buffer (1.2 mmol/L K₂HPO₄ and 0.3 mmol/L
33
34 KH₂PO₄, pH 7.4) made up in 100% D₂O and containing 0.005% sodium azide and 3.3
35
36 mmol/L TSP (3-trimethylsilyl propionate) as chemical shift reference. The sample was
37
38 shaken and 500 μL transferred into a 5 mm NMR tube for spectral acquisition. ¹H NMR
39
40 spectra were recorded at 600 MHz on a Bruker Avance spectrometer (Bruker BioSpin
41
42 GmbH, Rheinstetten, Germany) running TOPSPIN 2.0 software and fitted with a cryoprobe
43
44 and a 60 slot autosampler. The acquisition order was randomized with respect to collection
45
46 date and sample codes. Each ¹H NMR spectrum was acquired with 128 scans, 90° pulses
47
48 (14 μs), spectral width 8012.8 Hz, acquisition time 2.04 s and relaxation delay 2.0 s. The
49
50 noesygprr1d pre-saturation sequence was used to suppress the residual water signal with
51
52 low power selective irradiation at the water frequency during the relaxation delay and mixing
53
54 time (0.01s). Spectra were transformed with zero filling and 0.3 Hz line broadening, manually
55
56 phased, baseline corrected and referenced by setting the TSP methyl signal to 0 ppm.
57
58
59
60

1
2
3 Metabolites were identified using information found in the literature¹⁵⁻¹⁷, on the web (Human
4 Metabolome Database, <http://www.hmdb.ca/>), using Chenomx software, and by use of the
5
6
7 2D-NMR methods COSY, HSQC, and HMBC.
8

9
10 Plasma (200 μL) was mixed with 400 μL saline solution (0.9% w/v NaCl in 90%/10%
11
12 $\text{H}_2\text{O}/\text{D}_2\text{O}$) and 500 μL were transferred to an NMR tube. Proton NMR spectra were
13
14 measured at 300 K using the same NMR equipment. Spectra were acquired using the
15
16 Bruker cpmgpr1d water suppression pulse sequence, with 32 k data points, spectral width
17
18 20.8 ppm, acquisition time 1.36 s, relaxation delay 2 s, 90° pulses (11 μs), spin-echo delay
19
20 0.4 ms, loop number 300 (giving a total echo time = 240 ms) and 128 transients per
21
22 spectrum. Free induction decays were zero filled and exponential line broadening of 1 Hz
23
24 was applied prior to Fourier transformation. Proton NMR spectra were referenced to the
25
26 anomeric α -glucose signal (δ 5.234 ppm).
27

28 29 *NMR data analysis*

30
31
32 NMR Spectra were prepared for statistical analysis using the Bruker AMIX software v3.9.
33
34 The spectra were divided along the horizontal axis into variable width “buckets” (or bins)
35
36 using the AMIX graphical editor to draw buckets that include, where possible, recognizably
37
38 complete individual peaks or multiplets. The intensities within each bucket were summed,
39
40 divided by the bucket width and the bucket intensities were normalized to the same total
41
42 intensity for each sample to give the final bucket table. Regions with only background noise,
43
44 the urea peak and the water resonance were not included in the buckets. This gave matrices
45
46 of 368 samples x 380 buckets for the urine NMR spectra and 363 samples by 101 buckets
47
48 for the plasma spectra.
49

50 51 *HPLC-TOF MS analysis*

52
53
54
55 A subset of 240 urine samples (0 and 6-h post chocolate) was defrosted and vortex mixed
56
57 before sampling. A portion of urine (1 mL) was centrifuged for 5 min at 9600 g and 150 μL
58
59
60

1
2
3 of the supernatant was transferred to a glass vial to which MilliQ water (450 μ L) was added.
4
5 The sample was vortex mixed. A portion of each individual sample (35 μ L) was taken and
6
7 pooled to make a quality control sample (PQC) representative of all samples in the sample
8
9 set. Sample analysis used an Agilent 1100 HPLC coupled to a Bruker Daltonics MicroTOF.
10
11 Sample (5 μ L) was injected onto a Phenomenex Gemini C18 column (150 x 2.1 mm, 3.0 μ m
12
13 at 25 $^{\circ}$ C) with a flow rate of 250 μ L/min. A gradient of 100% A (MilliQ water + 0.1% formic
14
15 acid) and 0% B (acetonitrile + 0.1% formic acid) was applied increasing B to 15% over 5 min
16
17 and then to 95% over 15 min and held at 95% for 4 min. The PQC was injected for the first
18
19 three runs and after each set of six injections for each batch (samples were randomized into
20
21 batches of 50 samples). The TOF scan was over 90-1000 amu in positive ESI mode. Mass
22
23 calibration was performed for each sample using reference masses of sodium formate ion
24
25 clusters to give a mass accuracy of 5 ppm. The Bruker raw data files were converted to
26
27 NetCDF and the metabolite feature data presented in the manuscript were generated
28
29 entirely using the Bioconductor (<http://www.bioconductor.org/software>) packages XCMS (v
30
31 1.22.1)¹⁸ running with default parameters under R (v 2.11.0). XCMS finds and integrates
32
33 peaks within small time and mass windows and produces a table of integrated intensities for
34
35 a set of features (identified by combined mass retention time labels) that are common to all
36
37 samples. Features are reported if they occur in more than half the samples in at least one of
38
39 the groups (*e.g.* control, treatment) so that intensities of features from say flavan-3-ol
40
41 metabolites may be close to zero in baseline samples. Each feature has an associated
42
43 median accurate mass which may be used for putative identification of species present via
44
45 database search (*e.g.* MZedDB, <http://maltese.dbs.aber.ac.uk:8888/hrmet/index.html>)¹⁹ or
46
47 from relevant literature¹¹. A total of 2900 features were extracted for subsequent data
48
49 analysis.
50

51 52 53 *Data Analysis* 54 55 56 57 58 59 60

1
2
3 Multivariate statistical analysis (Principal Component Analysis, PCA) was carried out using
4 the PLS Toolbox v5.5 (Eigenvector Research Inc., Wenatchee, WA) running within Matlab,
5 v7.6 (The MathWorks Inc., Natick, MA). Autoscaling was applied to the columns of the
6 bucket table. The same procedure was applied to the integrated intensities in the XCMS
7 table with the mass retention time features taking the place of NMR buckets as variates.
8
9

10
11
12
13
14 Univariate analyses were carried out on individual variates (NMR or LC/MS) in GraphPad
15 Prism v5.01 (GraphPad Software, San Diego, CA) using the Kruskal-Wallis test with Dunn's
16 post-test. The same software was used to plot the results of these analyses. A
17 comprehensive set of univariate analyses was also carried out on all buckets for the urine
18 NMR data using an in-house Matlab routine. The comparison of metabolic responses to the
19 three different chocolate types was performed on bucketed NMR spectra that were area
20 normalised followed by two stages of probabilistic scaling²¹. First, the three baseline (time t
21 = 0) spectra for an individual were scaled to their mean. Second, spectra collected at times t
22 = 2 h and t = 6 h were scaled to their corresponding adjusted baseline. Post-ingestion
23 difference spectra were calculated by subtraction of their corresponding adjusted baselines.
24 For both post-ingestion time points the differences in the spectral response of each bucket
25 were ranked by their Mack-Skillings statistic^{22, 23}. The top 162 & 223 buckets were found to
26 be significantly different at 2 h and 6 h respectively, based on a FDR of q = 0.05 [22], using
27 p-values based on 10⁷ within-block permutations^{22, 23}. The significance of the differences in
28 response at each bucket was also estimated from within-block permutations (Table S5).
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51

52 RESULTS

53
54 We recruited 42 healthy subjects, each receiving three acute treatments (flavan-3-ol-
55 enriched dark chocolate (EDC), standard dark chocolate low in flavan-3-ols (DC), or white
56
57
58
59
60

1
2
3 chocolate (WC) containing no flavan-3-ols) in random order. The three intervention days
4 were separated by two washout periods of at least two weeks. This crossover design
5 provided optimal statistical power as each subject acted as their own control.
6
7

8
9
10 *Dietary markers mainly contribute to the discrimination of the metabolite profiles*
11

12
13 Plasma NMR spectra were assessed by PLS-DA and showed differentiation between 0h and
14 later time points but no discrimination between the three chocolate treatments (Figure S2).
15 Differentiation was caused by elevation of lactate at 2h and aspartate, acetoacetate, acetone
16 and β -hydroxybutyrate levels at 6 h after ingestion²⁴.
17
18
19
20

21
22 A series of Principal Component Analysis (PCA) models were created from urine ¹H NMR
23 and LC/MS data to assess whether there was separation between dietary treatments at 0 h,
24 2 and 6 h post-ingestion and between the different time points for each treatment (Figure 1).
25 LC/MS data from the 2h samples was not recorded hence only the 0h and 6h groups were
26 analysed. Three 4 group PCA models were constructed: controls at 0 h, EDC-2h, DC-2h and
27 WC-2h; controls at 0 h, EDC-6h, DC-6h and WC-6h both for NMR data and controls at 0 h,
28 EDC-6h, DC-6h and WC-6h for LC/MS data. All three models showed partial overlap of dark
29 chocolate groups (EDC and DC) but clear discrimination between dark chocolate groups,
30 WC and the baseline group (0h) (Figure 1 a-c). Three treatment-based PCA models (EDC,
31 DC and WC) applied to 3 groups (0, 2 and 6h postprandially) also showed a clear separation
32 between 0 h and post-ingestion scores but the scores at 2 and 6 h post-ingestion groups
33 overlapped (Figure 1d-f and Figure S3 a-c).
34
35
36
37
38
39
40
41
42
43
44
45
46
47

48 The discrimination of samples from the EDC group and to some extent the DC group versus
49 the baseline group (0h) and WC group (seen on PC4 in Figure 1a and PC2 in Figure 2b)
50 was largely due to an increase in the intensity of buckets containing signals from epicatechin
51 derivatives, theobromine and its methylxanthine derivatives (Figure S3 d-e) in the EDC and
52 DC groups.
53
54
55
56
57
58
59
60




Figure 1.

Assignment of the dietary markers and their levels across the three chocolate treatments

Epicatechin derivatives and methylxanthines were detected in urine samples by both ^1H NMR and LC/TOF-MS. Comparison of HSQC and COSY spectra of 6h EDC and WC urines (same volunteer) revealed many new peaks in the EDC spectra that were not present in the WC. The signals were assigned as theobromine or epicatechin metabolites using information from the HMDB, literature, or via spiking (theobromine itself). Several buckets between 3.5 and 4.0 ppm containing signals arising from 3- and 7-methylxanthines and theobromine (3,7-dimethylxanthine) as well as the singlets from the corresponding xanthine purine rings at 8.03, 7.86 and 7.91 ppm were all strong markers in the urines from volunteers having ingested either DC or EDC (Figure 2 and Table 1).

1
2
3 Thanks to its higher sensitivity, numerous additional dietary metabolites were detected by
4 LC/MS as reported previously¹¹. Derivatives of theobromine (Figure 3) were identified in the
5 urines after DC and EDC consumption, namely 3- and 7-methyluric acids, 3,7-dimethyluric
6 acid, 6-amino-5[N-methylformylamino]-1-methyluracil (AMMU), as well as intact theobromine
7 (Table 2). Several metabolites indicative of EDC and DC consumption were identified
8 including hydroxynicotinate, caffeine and vanilloylglycine. Several metabolites of catechins
9 were also detected, *i.e.* epicatechin monosulfate, 4-hydroxy-5-(3,4-dihydroxyphenyl)-
10 valerate, the glucuronide and sulfate metabolites of 5-(3',4'-dihydroxyphenyl)- γ -valerolactone
11 and 3'-methoxy-4'-hydroxyphenylvalerolactone and its glucuronide. Those metabolites were
12 all observed 6 h post-ingestion and their levels significantly increased compared with levels
13 at 0 h. There was a decrease in hippurate levels from 0 h to 6 h postprandial after
14 consumption of all types of chocolate (Figure 3). A set of features that were significantly
15 enhanced in white chocolate was noticed although the identification of the compounds
16 remains to be established (Table S4).
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2.




Figure 3.

1
2
3 *Concentration of flavanol-3-ols and methylxanthines in chocolate.*
4
5

6 The combined caffeine and theobromine concentrations were quite similar in both dark
7 chocolates. The flavanol-3-ol enriched chocolate had a combined content of 1.12% whilst
8 the standard dark chocolate contained 1.23%. (Table S1). The enriched dark chocolate
9 contained 1.5% total flavonoids compared to 0.64% in the standard dark chocolate (Table
10 S3). Neither methylxanthines nor flavonoids were detected in the white chocolate.
11
12
13
14
15

16
17 *Changes in endogenous metabolite levels across the three chocolate treatments*
18
19

20 The urinary ¹H NMR spectra recorded were segmented into 380 buckets and univariate
21 analyses were carried out on the bucket intensities. Of these buckets, 223 had a p-value
22 lower than 0.05 when the three chocolate treatments were compared at 6 h (see Table S5).
23 The markers with the lowest p values were assigned to catechin and xanthine derivatives.
24 Interestingly, a subset of endogenous metabolites was affected by the chocolate intake,
25 mainly by the two dark chocolates (Table 3). Urinary levels of several amino acids (Ala, Val,
26 Gly) and organic acids (2- and 3-hydroxyisobutyrate, 3-hydroxyisovalerate) were significantly
27 decreased 6 h after intake of both dark chocolates compared with white chocolate and all
28 followed the same trend: mean level in flavan-3-ol-enriched dark chocolate < dark chocolate
29 < white chocolate. Additionally, a few energy compounds also followed the same trend,
30 namely creatinine, N¹-methylnicotinamide (NMA) and lactate. Interestingly pyruvate followed
31 an inverse trend where levels were increased by flavan-3-ol-enriched dark chocolate and
32 dark chocolate compared with white chocolate. Levels of tyrosine and its microbial product
33 (para-hydroxyphenylacetate) were also elevated after consumption of both dark chocolates
34 (Table 3). Trends for selected markers can be found in Figure 4.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 4.

Changes in metabolite levels associated with gender and age

Differences in levels of the main xanthine metabolites (3- and 7-methylxanthine and theobromine) and the buckets at 6.11, 6.13 and 6.15 ppm reflecting catechin derivatives were investigated further by subdividing the treatment groups according to gender, BMI and age, at 2- and 6-h post chocolate. Only theobromine excretion levels showed a significant difference with respect to gender, with higher levels being excreted by females compared with males. The gender differences were being observed for both dark chocolates at the 6 h and for standard dark chocolate at the 2 h time point. There was also an effect of the age on the levels of the same metabolite with a higher excretion for volunteers aged 29 or younger compared with volunteers older than 54 (Figure 5).




Figure 5.

DISCUSSION

In this study we assessed acute effects of consumption of flavan-3-ol-enriched dark chocolate in comparison with a standard dark and a white chocolate on plasma and urinary ¹H NMR profiles and urinary MS profiles in healthy humans. Both urinary and plasma profiles showed wide-scale metabolite composition changes post-chocolate intake. Multivariate and univariate analyses coupled to metabolite identification revealed that the major differences between treatments were found in urine and changes were related to both intake markers as well as markers of endogenous metabolism.

There was no differentiation between the three treatment groups in the plasma ¹H NMR profiles contrary to the many changes detected in the urinary profiles. No theobromine or catechin derived metabolites were found because plasma concentrations of these were under the detection limit for NMR.

Changes detected in the urinary profiles principally affected a number of NMR buckets between 3.00 and 4.00 ppm, and in the regions of 6.10 and 8.00 ppm after both dark chocolate treatments. Those signals were attributed to metabolized compounds of dietary origin (catechin²⁵ and methylxanthine²⁶ derivatives). Interestingly Martin et al¹² detected an increase in levels of two unknown singlets at 7.85 and 7.91 ppm after one week of chronic intake of dark chocolate which were most likely peaks arising from 7-methylxanthine and

1
2
3 theobromine (see Table 1). The levels of an unknown at 3.39 ppm detected in the present
4
5 study were also increased in their study. Caffeine itself was not detected in the urinary
6
7 spectra because the levels were too low to be detected. For comparison the abundance of
8
9 theobromine in the dark chocolates was six times that of caffeine (supplementary Table 3)
10
11 yet only theobromine and two main products (3 and 7-methyl xanthines) were detected by ¹H
12
13 NMR. 6-amino-5-[N-methylformylamino]-1-methyluracil (AMMU) is the main degradation
14
15 product after caffeine intake ²⁷. In our study, 3-methylxanthine, 7-methylxanthine and AMMU
16
17 are the main urinary products of theobromine ²⁶ (Figure 3g). Caffeine degradation may have
18
19 marginally contributed to the AMMU levels detected by LC/MS. The LC/MS on 6 h urines
20
21 demonstrated changes in metabolites of polyphenols and alkaloids metabolites and also
22
23 showed the occurrence of microbial metabolites. Our results are in agreement with other
24
25 studies ^{11, 25}.

26
27
28 However, there was no increase in hippurate levels in our study although this metabolite of
29
30 microbial origin has been recognized as the main excretion product from polyphenols such
31
32 as catechins and from green and black tea consumption ^{28, 29}.

33
34
35 There was an increase of para-hydroxyphenylacetate (HPA) 6 h after ingestion of both dark
36
37 chocolates. Hydroxyphenylacetate is related to food intake and breakdown processes by
38
39 gut microbiota ³⁰. It originates from dietary phenolic compounds, including the catechins
40
41 contained in dark chocolate. The increase of HPA was accompanied with an increase of
42
43 tyrosine, an abundant component of cacao seeds¹¹.

44
45
46 We did not observe changes in levels of citric acid cycle compounds such as succinate or
47
48 citrate but, as in a study on consumption of black tea polyphenols ³¹, we saw an increase of
49
50 pyruvate in urine. Additionally, we saw a reduction in lactate at 6 h post-intake of flavan-3-ol-
51
52 enriched dark chocolate. The lactate levels increased at 6h for WC compared to 0h and to
53
54 EDC or DC at 6h. Whilst we cannot elucidate the mechanisms of such changes based on
55
56 metabolomics results alone, it is possible that, glycolysis and/or gluconeogenesis might be
57
58
59
60

1
2
3 enhanced by the catechin-rich chocolate thus increasing levels of excreted pyruvate^{32, 33}.
4
5 Concomitantly, a large intake of catechins might have affected anaerobic respiration, leading
6
7 to a reduced production of lactate. Furthermore, the urinary levels of four glucogenic amino
8
9 acids, arginine, valine, alanine and glycine, were reduced after consumption of flavan-3-ol-
10
11 enriched dark chocolate, suggesting a possible redirection of the energy metabolism towards
12
13 gluconeogenesis³³ following catechin intake (Table 3).
14

15
16 The urinary levels of both creatinine and N¹-methylnicotinamide (NMA) were reduced
17
18 following intake of both dark chocolates but creatinine was increased by WC at 6h. The
19
20 levels of creatinine and NMA in WC were higher than EDC or DC at 6h as shown in Figure 4.
21
22 Creatinine is a clearance product from phosphocreatine (PCr) which itself is a phosphate
23
24 donor for sudden adenosine triphosphate (ATP) demand and NMA arises from dietary niacin
25
26 and from tryptophan metabolism³⁴. Wang *et al*³⁵ proposed a link between creatinine urinary
27
28 levels, oxidative stress and modulation of oxidative stress by antioxidants which could be
29
30 attributed to catechins in both dark chocolates. A decrease in creatinine may be associated
31
32 with a better regulation of the PCr pool and ATP usage. Note that a decrease in creatinine
33
34 has already been observed by Martin *et al*¹². This similarity indicates that both acute and
35
36 chronic intake of dark chocolate may affect the energy metabolism in a similar way.
37

38
39 A decrease in NMA would indicate an upregulation towards the production of NAD⁺ and
40
41 energy expenditure³⁶. Also NMA is an activator of prostacyclin (PGI₂) production which may
42
43 regulate thrombotic as well as inflammatory processes in the endothelial vascular system via
44
45 anti-platelet effects^{37, 38}. In our case, decreases in creatinine and NMA urinary levels may
46
47 indicate effects on metabolic regulation bringing potential health benefits through the action
48
49 of chocolate bioactive ingredients.
50

51
52
53 Martin *et al*¹² showed that dark chocolate had an effect on the energy metabolism and on
54
55 metabolites from gut microbiota. Products from the gut microbiota are commonly found in
56
57 biological fluids including urine, plasma or faecal waters³⁹. These include methylamine,
58
59
60

1
2
3 dimethylamine (DMA), trimethylamine (TMA), and trimethylamine-N-oxide (TMAO) and
4 related metabolites (dimethylglycine) which may originate from dietary choline.
5
6
7

8 We observed a urinary decrease of DMA in urine 6 h after ingestion of both dark chocolates.
9
10 Dimethylamine is a product of TMA and TMAO. It is difficult to assess if a reduction of DMA
11 is beneficial to health. Wang *et al* ⁴⁰ reported that supplementation of mice with choline,
12 TMAO or betaine promoted upregulation of multiple macrophage scavenger receptors linked
13 to atherosclerosis, and supplementation with choline or TMAO promoted atherosclerosis.
14 Therefore, it appears that lower endogenous levels of methylamines may be beneficial to
15 health.
16
17
18
19
20
21
22

23 The short chain hydroxy acids, 3-hydroxyisovalerate, 2-hydroxyisobutyrate and 3-
24 hydroxyisobutyrate, were reduced following intake of both dark chocolates but increased
25 from 0h to 6h after WC. These acids are normally found at low levels in urine of healthy
26 individuals ⁴¹ and at high levels in urine and blood of patients suffering from branched-chain
27 organic acidurias ⁴² or other acidosis ⁴³. Both 3-hydroxyisovalerate and 3-hydroxyisobutyrate
28 are intermediates in the catabolism of branched amino acids such as leucine and valine and
29 2-hydroxyisobutyrate has been reported as being a gut metabolite increased in the urine of
30 healthy humans eating a diet high in proteins ⁴¹. Newgard *et al* ⁴⁴ compared the blood
31 profiles of obese and lean humans and showed a link between a branched-chain amino
32 acid-related metabolite signature and increased catabolism of branched amino acids and
33 correlation with insulin resistance. In our case, the reduced branched amino acids
34 catabolism may be part of the change in energy metabolism observed after eating dark
35 chocolate. Regulating the catabolism of these amino acids may be a positive benefit on
36 glucose metabolism.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51

52 Caffeine and theobromine are the most abundant methylxanthines in chocolate and their
53 physiological effects are well recognised ². They are extensively metabolized (urinary
54
55
56
57
58
59
60

1
2
3 recovery of < 2%) and are known to be metabolized by cytochrome P450 (CYP450)
4
5 enzymes during phase II excretion ^{27, 45}.
6
7

8 In this study, females excreted on average almost twice as much theobromine as males 6 h
9
10 after intake of both dark chocolates and there was also a significant dependence of
11
12 theobromine excretion on age with flavan-3-ol-enriched dark chocolate treatment. Some
13
14 previous studies reported no gender effect on elimination following an intake of caffeine,
15
16 theobromine or theophylline ^{27, 46, 47} while others reported the inverse ⁴⁵. Additionally, Agarwal
17
18 ⁴⁸ showed that *in vitro* arginine⁸-vasopressin (AVP) levels in blood from male and female
19
20 donors differed and that theophylline and a related xanthine could interfere with the platelet
21
22 aggregation capacity of AVP in human platelet-rich plasma. This result points to a multiple
23
24 factor effect (including gender) and/or expression of CYP450 enzymes (CYP1A2 in particular
25
26 ⁴⁷) on compounds and metabolized products which in turn could affect the host metabolism.
27
28

29 Conclusion

30
31
32
33 These effects may have arisen from consumption of both the flavanol-3-ols and the
34
35 methylxanthines. In many cases there was similar response to both dark chocolates and the
36
37 increased flavonoid content did not show any dose response even though the enriched dark
38
39 chocolate contained some 2.4 times the flavonoid content of the standard dark chocolate.
40
41

42 In summary, this NMR and MS-based metabolomic study has shown that dietary markers
43
44 are traceable in the urine of healthy individuals after an acute intake of flavan-3-ol-enriched
45
46 dark and standard dark chocolate. Bioactive compounds and metabolized products were
47
48 also found to have an effect on the endogenous metabolism and the gut microbial activity
49
50 affecting in particular several pathways relating to energy metabolism and the nicotinate
51
52 pool.
53
54

55 Associated Content available

56
57
58 Subjects
59
60

1
2
3 Study design

4 Biofluid and blood sampling

5
6 Creatinine assay

7
8
9
10 Figure S1. Flow chart of the study design

11
12 Figure S2. PC scores, PC loadings from PCA analysis on blood plasma data

13 Figure S3. PC scores, PC loadings from PCA analysis on urine data

14
15 Table S1. Nutritional composition of chocolate bars

16
17 Table S2. Baseline characteristics for study subjects

18
19 Table S3. Flavonoid content of chocolate bars

20
21 Table S4. Urinary MS markers for white chocolate

22
23
24 Table S5. NMR bucket markers for the comparison between 4 groups: 0 h, EDC, DC and
25
26 WC treatment groups

27 28 **COMPETING FINANCIAL INTERESTS**

29
30
31 None of the authors declared a conflict of interest.

32 33 **ACKNOWLEDGMENTS**

34
35
36
37 This work was supported by the Biotechnology & Biological Sciences Research Council
38 (BBSRC) Competitive Strategic Grant and the Scottish Government Rural and Environment
39 Research and Analysis Directorate (RERAD). All chocolates were specifically produced for
40
41 this study and provided free of charge by Natraceutical Group, Valencia, Spain.

42
43
44
45 We thank the volunteers who participated in the study.

46 47 **AUTHOR CONTRIBUTIONS**

48
49
50
51 The authors' responsibilities were as follow: LMO, GGD, PAK and BDR: designed and
52
53 conducted the nutritional intervention; GLG: designed the metabolomic analyses; MP and
54
55 SS: performed the MS analysis; LMO and GLG: performed the NMR analysis; IJC and GLG:
56
57 analyzed the NMR and MS data; EKK and HST: performed some statistical analyses; GLG:
58
59
60

1
2
3 interpreted the NMR and MS data; GLG: wrote the manuscript and all authors: provided
4
5 comments, read and approved the final manuscript.
6
7

8 REFERENCES

9
10
11 1. Aron, P. M. & Kennedy, J. A. Flavan-3-ols: Nature, occurrence and biological activity. *Mol.*
12
13 *Nut. and Food Res.* **2008**, *52*, 79-104.

14
15
16 2. Franco, R., Oñatibia-Astibia, A. & Martínez-Pinilla, E. Health benefits of methylxanthines
17
18 in cacao and chocolate. *Nutrients* **2013**, *5*, 4159-4173.

19
20
21 3. Hooper, L. *et al.* Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis
22
23 of randomized controlled trials. *Am. J. Clin Nutr.* **2008**, *88*, 38-50.

24
25
26 4. Ostertag, L. M., O'Kennedy, N., Kroon, P .A., Duthie, G. G.& De Roos, B. Impact of
27
28 dietary polyphenols on human platelet function--a critical review of controlled dietary
29
30 intervention studies. *Mol. Nutr. Food Res.* **2010**, *54*, 60-81.

31
32
33 5. Bachmair, E. M., Ostertag, L. M., Zhang, X., & de Roos, B. Dietary manipulation of platelet
34
35 function. *Pharmacol Ther.* **2014**, *144*, 97-113.

36
37
38 6. Fredholm, B. B. & Persson, C. G. Xanthine derivatives as adenosine receptor antagonists.
39
40 *Eur. J. Pharmacol.* **1982**, *81*, 673–676.

41
42
43 7. Dulloo, A. G., Seydoux, J., Girardier, L. Potentiation of the thermogenic antiobesity effects
44
45 of ephedrine by dietary methylxanthines: adenosine antagonism or phosphodiesterase
46
47 inhibition? *Metabolism* **1992**, *41*, 1233-1141.

48
49
50 8. Dulloo, A. G., Seydoux, J., Girardier, L., Chantre, P. & Vandermader, J. Green tea and
51
52 thermogenesis: interactions between catechin-polyphenols, caffeine and sympathetic
53
54 activity. *Int. J. Obes. Relat. Metab. Disord.* **2000**, *24*, 252-258.
55
56
57
58
59
60

- 1
2
3 9. Rios, L. Y. *et al.* Chocolate intake increases urinary excretion of polyphenol-derived
4 phenolic acids in healthy human subjects. *Am. J. Clin. Nutr.* **2003**, *77*, 912-918.
5
6
7
8 10. Urpi-Sarda, M. *et al.* Epicatechin, procyanidins, and phenolic microbial metabolites after
9 cocoa intake in humans and rats. *Anal. Bioanal. Chem.* **2009**, *394*, 1545-1556.
10
11
12
13 11. Llorach, R., Urpi-Sarda, M., Jauregui, O., Monagas, M., & Andres-Lacueva, C. An LC-
14 MS-based metabolomics approach for exploring urinary metabolome modifications after
15 cocoa consumption. *J. Proteome Res.* **2009**, *8*, 5060-5068.
16
17
18
19
20 12. Martin, F. P. *et al.* Metabolic effects of dark chocolate consumption on energy, gut
21 microbiota, and stress-related metabolism in free-living subjects. *J. Proteome Res.* **2009**, *8*,
22 5568-5579.
23
24
25
26
27
28 13. Ostertag, L. M. *et al.* Flavan-3-ol-enriched dark chocolate and white chocolate improve
29 acute measures of platelet function in a gender-specific way – a randomized-controlled
30 human intervention trial. *Mol. Nut. Food Res.* **2013**, *57*, 181-202.
31
32
33
34
35 14. Cooper, K. A. *et al.* Rapid reversed phase ultra-performance liquid chromatography
36 analysis of the major cocoa polyphenols and inter-relationships of their concentrations in
37 chocolate. *J. Agric. Food Chem.* **2007**, *55*, 2841–2847.
38
39
40
41
42 15. Nicholson, J. K., Foxall, P. J. D., Spraul, M., Farrant, R. D. & Lindon, J. C. 750 MHz ¹H
43 and ¹H-¹³C NMR spectroscopy of human blood plasma. *Anal. Chem.* **1995**, *67*, 793-811.
44
45
46
47 16. Bouatra, S. *et al.* The human urine metabolome, *PLoS One* **2013**, *8*, e73076.
48
49
50
51 17. Calvani, R. *et al.* Fecal and urinary NMR-based metabolomics unveil an aging signature
52 in mice *Exp. Gerontol.* **2014**, *49*, 5-11.
53
54
55
56
57
58
59
60

- 1
2
3 18. Smith, C. A., Want, E. J., O'Maille, G., Abagyan, R., & Siuzdak, G. XCMS: processing
4 mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching,
5 and identification. *Anal. Chem.* **2006**, *78*, 779-787.
6
7
8
9
10 19. Draper, J. *et al.* Metabolite signal identification in accurate mass metabolomics data with
11 MZedDB, an interactive m/z annotation tool utilising predicted ionisation behaviour 'rules'.
12 *BMC Bioinformatics.* **2009**, *10*, 227-242.
13
14
15
16
17 20. Rajalahti, T. *et al.* Biomarker discovery in mass spectral profiles by means of selectivity
18 ratio plot. *Chemom. Intell. Lab. Sys.* **2009**, *95*, 35-48.
19
20
21
22 21. Dieterle, F., Ross, A., Schlotterbeck, G., & Senn, H. Probabilistic quotient normalization
23 as robust method to account for dilution of complex biological Mixtures. Application in ¹H
24 NMR metabonomics. *Anal. Chem.* **2006**, *78*, 4281-4290).
25
26
27
28
29 22. Mack, G. A., & Skillings, J. H. A Friedman-type rank test for main effects in a two-factor
30 ANOVA. *J. Amer. Statist. Assoc.* **1980**, *75*, 947-951.
31
32
33
34 23. Hollander, M., & Wolfe, D. A. *Nonparametric statistical methods*. 2nd edition, Chichester,
35 Wiley, 1999, p 343-353.
36
37
38 24. Bales, J.R., Bell. J.D., Nicholson, J.K., Sadler, P.J.¹H NMR studies of urine during
39 fasting: excretion of ketone bodies and acetylcarnitine. *Magn. Reson. Med.* **1986**, *3*, 849-
40 856.
41
42
43
44
45 25. Fardet A *et al.* A liquid chromatography-quadrupole time-of-flight (LC-QTOF)-based
46 metabolomic approach reveals new metabolic effects of catechin in rats fed high-fat diets. *J.*
47 *Proteome Res.* **2008**, *7*, 2388-2398.
48
49
50
51
52 26. Tarka, S. M., Arnaud, M., Dvorchik, B. H. & Vesell, E. S. Theobromine kinetics and
53 metabolic disposition. *Clin. Pharmacol. Ther.* **1983**, *34*, 546-555.
54
55
56
57
58
59
60

- 1
2
3 27. Arnaud, M. J. Pharmacokinetics and metabolism of natural methylxanthines in animal
4 and man. *Handb. Exp. Pharmacol.* **2011**, *200*, 33-91.
5
6
7 28. Clifford, M.N., Copeland, E.L., Bloxsidgem, J.P., Mitchell, L.A. Hippuric acid as a major
8 excretion product associated with black tea consumption. *Xenobiotica* **2000**, *30*, 317-326.
9
10
11 29. Mulder, T.P., Rietveld, A.G., van Amelsvoort, J.M. Consumption of both black tea and
12 green tea results in an increase in the excretion of hippuric acid into urine. *Am. J. Clin. Nutr.*
13 **2005**, *81*, 256S-260S.
14
15
16 30. Li, M. *et al.* Symbiotic gut microbes modulate human metabolic phenotypes. *Proc. Natl.*
17 *Acad. Sci. U S A.* **2008**, *105*, 2117-2122.
18
19
20 31. Daykin, C. A. *et al.* Nuclear magnetic resonance spectroscopic based studies of the
21 metabolism of black tea polyphenols in humans. *J. Agric. Food Chem.* **2005**, *53*, 1428-1434.
22
23
24 32. Van Dorsten, F.A., Daykin, C.A., Mulder, T.P., Van Duynhoven, J.P. Metabonomics
25 approach to determine metabolic differences between green tea and black tea consumption
26 *J. Agric. Food Chem.* **2005**, *54*, 6929-6938.
27
28
29 33. Khakimov, B *et al.* New Nordic diet versus average Danish diet: A randomized controlled
30 trial revealed healthy long-term effects of the New Nordic diet by GC-MS blood plasma
31 metabolomics *J. Proteome Res.* **2016**, *15*, 1939-1954.
32
33
34 34. Takahashi, K., Okunom A., Fukuwatarim T. & Shibata, K. Comparison of the
35 nicotinamide catabolism among rat strains. *Biosci. Biotechnol. Biochem.* **2009**, *73*, 274-279.
36
37
38 35. Wang, Y. *et al.* A metabonomic strategy for the detection of the metabolic effects of
39 chamomile (*Matricaria recutita* L.) ingestion. *J. Agric. Food Chem.* **2005**, *53*, 191-196.
40
41
42 36. Kraus *et al.* Nicotinamide *N*-methyltransferase knockdown protects against diet-induced
43 obesity. *Nature* **2014**, *208*, 258-264.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 37. Przygodzki, T., Kazmierczak, P., Sikora, J. & Watala, C. 1-methylnicotinamide effects on
4 the selected markers of endothelial function, inflammation and haemostasis in diabetic rats
5
6
7 *Eur. J. Pharmacol.* **2010**, *640*, 157-162.
8
9
10 38. Mogielnicki, A., Kramkowski, K., Pietrzak, L. & Buczko, W. N-methylnicotinamide inhibits
11 arterial thrombosis in hypertensive rats. *J. Physiol. Pharmacol.* **2007**, *58*, 515-527.
12
13
14
15 39. Martin, F.P. et al. Probiotic modulation of symbiotic gut microbial-host metabolic
16 interactions in a humanized microbiome mouse model. *Mol. Syst. Biol.* **2008**, *4*, 157.
17
18
19
20 40. Wang, Z et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular
21 disease. *Nature* **2011**, *472*, 57-63.
22
23
24
25 41. Yap, I. K. et al. Metabolome-wide association study identifies multiple biomarkers that
26 discriminate north and south Chinese populations at differing risks of cardiovascular disease:
27 INTERMAP study. *J. Proteome Res.* **2010**, *9*, 6647-6654.
28
29
30
31 42. Ogier de Baulny, H. & Saudubray, J. M. Branched-chain organic acidurias. *Semin.*
32 *Neonatal.* **2002**, *7*, 65-74.
33
34
35
36 43. Shigematsu, Y. et al. Changing plasma and urinary organic acid levels in a patient with
37 isovaleric acidemia during an attack. *Pediatr. Res.* **1982**, *16*, 771-775.
38
39
40
41 44. Newgard et al. A Branched-Chain Amino Acid-Related Metabolic Signature that
42 Differentiates Obese and Lean Humans and Contributes to Insulin Resistance. *Cell Metab.*
43 **2009**, *9*, 311-326.
44
45
46
47 45. Relling, M. V., Lin, J. S., Ayers, G. D. & Evans, W. E. Racial and gender differences in N-
48 acetyltransferase, xanthine oxidase, and CYP1A2 activities. *Clin. Pharmacol. Ther.* **1992**,
49 *52*, 643-658.
50
51
52
53
54 46. Begas E., Kouvaras, E., Tsakalof, A., Papakosta, S. & Asproini, E. K. In vivo evaluation
55 of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample
56
57
58
59
60

by the RP-HPLC monitoring of caffeine metabolic ratios. *Biomed Chromatogr.* **2007**, *21*, 190-200.

47. Chung, W. G., Kang, J. H., Park, C. S., Cho, M. H. & Cha, Y. N. Effect of age and smoking on in vivo CYP1A2, flavin-containing monooxygenase, and xanthine oxidase activities in Koreans: determination by caffeine metabolism. *Clin Pharmacol Ther.* **2000**, *67*, 258-266.

48. Agarwal, K.C. Modulation of vasopressin actions on human platelets by plasma adenosine and theophylline: gender differences. *J. Cardiovasc. Pharmacol.* **1993**, *21*, 1012-1018.

Table 1. Exogenous urinary NMR markers for Enriched dark (EDC) and dark chocolate (DC) 6 hours after intake

Fold: EDC compared to white chocolate (WC) the control group
underlined chemical shift: used for data analysis

Bucket group	δ_H ppm	δ_C ppm	Metabolite identification	p value t-test EDC vs WC	Fold EDC/WC
1	2.59	.	catechin derivatives (C ring)	4E-08	1.4
2	2.79	30.1	epicatechin derivatives (C ring)	2.E-19	1.5
3	2.94, 2.95, 2.98, <u>3.00</u> , 3.01	30.3	epicatechin/polymer derivatives (C ring)	2.E-18	2.0
4	3.39	31.9	?	2.E-21	2.0
5	3.49	31.9	theobromine	3.E-11	3.0
6	3.53	32.2	3-methylxanthine	8.E-09	1.7
7	3.92	36.2	7-methylxanthine	7.E-14	2.4
8	3.94	36.2	theobromine	2.E-10	2.0
9	4.00	.	catechin derivatives (C ring)	4.E-10	0.8
10	5.08, 5.11, 5.14	80.8, 81.2	polymer catechin derivatives (C ring)	buckets not drawn	
11	6.11, 6.13, 6.15, <u>6.44</u> , 6.64	98.1, 98.8, 103.4, 105.0	all catechin derivatives (A ring mainly)	9.E-22	11.8
12	6.94 - <u>7.31</u>	.	all catechin derivatives (B ring mainly)	2.E-12	1.7
13	7.86	147.0	7-methylxanthine	5.E-12	3.5
14	7.91	146.8	theobromine	6.E-22	3.7
15	8.03	144.8	3-methylxanthine	2.E-13	2.2

Table 2. Urinary MS markers for Enriched dark (EDC) and dark chocolate (DC) 6 hours after intake
 Fold: EDC compared to white chocolate (WC) the control group
 * ion seen in the raw data but not detected by the deconvolution approach

Marker group	Marker ions	Metabolite identification	Retention time (min)	Theoretical mass [M+H] ⁺	p value t-test EDC vs WC	Fold EDC/WC	
1	140.035 [M+H] ⁺	hydroxynicotinic	4.3	140.034	2.E-07	4	
2	199.084 [M+H] ⁺	AMMU	5.7; 8.2	199.083	3.E-12	5	
	171.087 [M+H-H ₂ O] ⁺				2.E-09	4	
3	185.091	?	7.2		6.E-11	3	
4	260.064	?	8.4		5.E-13	24	
5	321.085 [M+H] ⁺	?	8.8		2.E-12	8	
	343.071 [M+Na] ⁺				8.E-13	750	
6	547.15 [3M+H] ⁺	7 and 3-methyl-uric	9.2	365.095	7.E-05	29	
	365.101 [2M+H] ⁺				7.E-03	2	
	183.052 [M+H] ⁺				4.E-04	2	
7	167.057 [M+H] ⁺	7 and 3-methylxanthine	9.5	167.056	5.E-11	5	
	333.108 [2M+H] ⁺				1.E-09	9	
8	197.057 [M+H] ⁺	dimethyluric	9.9	197.0669	2.E-09	3	
9	181.072 [M+H] ⁺	theobromine	10.7	181.072	2.E-17	10	
	399.099 [2M+K] ⁺				2.E-14	8	
10	420.091	4-hydroxy-5-(3,4-dihydroxyphenyl)-valeric acid	11.8	209.081	1.E-05	42	
	425.110				3.E-05	8	
	209.082 [M+H-H ₂ O] ⁺				.	*	
11	226.073 [M+H] ⁺	vaniloylglycine	12.1	226.071	3.E-08	5	
	151.042 [M+H-glycine] ⁺				1.E-08	3	
12	568.108	?	12.4		2.E-08	59	
	547.176				1.E-06	16	
13	195.089 [M+H] ⁺	caffeine	12.5	195.088	4.E-05	2	
14	385.116	5-(3',4'-dihydroxyphenyl)-valerolactone glucuronide	13.3	209.081	385.113	1.E-06	61
	407.115 [M+Na] ⁺				9.E-10	60	
	209.124 [M+H-GlcA] ⁺				1.E-06	9	
14	399.135 [M+H] ⁺	3'-methoxy-4'-hydroxyphenylvalerolactone glucuronide	13.4	399.129	1.E-04	8	
	223.096 [M+H-GlcA] ⁺				223.096	3.E-05	8
	421.122 [M+Na] ⁺				2.E-06	19	
15	369.113 [M+H] ⁺	O-Feruloylquininate ?	13.6	391.100	2.E-06	19	
	391.106 [M+Na] ⁺				5.E-06	13	

16	289.040 [M+H] ⁺	5-(3',4'-dihydroxyphenyl)-valerolactone-sulfate	17.7	289.038	2.E-05	23
17	371.044	epicatechin-O-sulfate	22.2	371.043	3.E-09	2400

Table 3. Changed in levels of endogenous urinary NMR markers for Enriched dark (EDC) and dark chocolate (DC) 6 hours after intake

Trends: EDC and DC compared to white chocolate (WC) the control group

underlined chemical shift: used for data analysis

* could correspond to chemical groups from amino acids such as ornithine or citrulline

Marker group	δ (ppm)	Metabolite identification	Trends	Class	P value t-test EDC vs WC	Fold EDC/WC
1	<u>3.05</u> , 4.07	creatinine	down	energy metabolism	2E-08	0.8
2	1.68, <u>1.95</u>	arginine	down	amino acid	8E-05	0.9
3	<u>1.00</u> , <u>1.05</u>	valine	down	amino acid	4E-06	0.9
4	1.49	alanine	down	amino acid	4E-05	0.8
5	3.57	glycine	down	amino acid	5.E-03	0.8
6	1.78	unknown at 1.78 ppm	down	.	2E-07	0.8
7	1.88	unknown at 1.88 ppm	down	.	9E-05	0.9
8	<u>4.48</u> , <u>9.28</u>	N-methylnicotinamide	down	pyridine, metabolite of niacin (vitB3)	2.E-04	0.8
9	2.07	N-acetylated compounds	down	(phase II and other pathways)	8E-06	0.9
10	2.73	dimethylamine	down	amine (bacterial origin)	3.E-02	0.9
11	1.28	3-hydroxyisovalerate	down	short chain hydroxy acid, leucine catabolism	2.E-04	0.8
12	1.36	2-hydroxyisobutyrate	down	short chain hydroxy acid	2.E-04	0.9
13	1.08	3-hydroxyisobutyrate	down	short chain hydroxy acid, valine catabolism	1.E-03	0.9
14	1.34	lactate	down	short chain fatty acid	2.E-04	0.8
15	2.37	pyruvate	up	glycolysis, gluconeogenesis	2E-06	1.2
16	6.86	4-hydroxyphenyl acetate	up	phenolic compound (bacterial origin)	7.E-03	1.2
17	<u>6.90</u> , <u>7.19</u>	tyrosine	up	amino acid	1.E-03	1.3
18	4.4	unknown at 4.40 ppm	up	.	2.E-02	1.2

Figure Legends

Figure 1. PCA score plots from urine samples at baseline (0 h) and at the specified time for each of the three chocolate treatments (a) NMR 0 h & 2 h, (b) NMR 0 h & 6 h, (c) LC/MS 0 h & 6 h. PCA score plots from urinary NMR spectra of 0-hour, 2-hours and 6-hours samples for flavan-3-ol-enriched dark chocolate (EDC) (d), dark chocolate (DC) (e) and white chocolate (WC) (f)

Figure 2. Partial 600MHz ^1H NMR spectra of urines from one subject: (A) baseline and (B)-(D) after treatment indicated at 6 h

Figure 3. MS intensity for markers of enriched dark chocolate (EDC) and dark chocolate (DC) intake and hippurate 6 hours after intake. White (WC) chocolate is the control group. All have p value < 0.0001 (Kruskal-Wallis test on 4 groups). 0-hour n=126; EDC, 6-hours n=38, DC, 6-hours n=42 and WC, 6-hours n=39. Selected m/z ions were m/z 183.052, 167.057, 181.072, 371.044, 420.091, 180.066 (a to f respectively). (g) Map of the theobromine pathway. Cytochrome P450 (CYP2E1, CYP1A2) and N-acetyltransferase 2 (NAT2), are involved in the activation or detoxification of various xenobiotic compounds including alkaloid like theobromine (adapted from Arnaud ²⁷)

Figure 4. NMR intensity/ concentration of a selection of endogenous urine metabolites for the three chocolate treatments. (all groups) n= 39-42. Plots are for the times specified from data in NMR buckets (a) creatinine at 3.05 ppm, (b) creatinine at 4.07 ppm, (c) creatinine (KONELAB assay), (d) N¹-methylnicotinamide (NMA) at 4.48 ppm, (e) tyrosine at 6.90 ppm and (f) pyruvate at 2.37 ppm. * p < 0.05 Mann-Whitney test

Figure 5. NMR intensity of theobromine at 7.91 ppm in urines at 0 h (baseline) or 6 h (treatments) showing (a) overall variation with treatment, (b) grouping by treatment and gender, (c) grouping by treatment and age (younger < 29 y, older > 54 y). (all groups) n= 14-42 n=14-42 per group. Note that because of the crossover design each treatment group has its own baseline (0 h) samples. *p < 0.05 Mann-Whitney test

For TOC only

